Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

By B. Coiffier, B. Pro, H. Prince, F. Foss, L. Sokol, M. Greenwood, D. Caballero, P. Borchmann, F. Morschhauser, M. Wilhelm and 8 more. Journal of Clinical Oncology, 2012

642 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/cba2c46aaa35e1a8070dab1bb8aff51d82943f6d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Guangdi Wang
2. Tien L. Huang
3. Madhusoodanan Mottamal
4. Shilong Zheng

Citations in the corpus

• Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents (2015, background): “The most common grade 3 and 4 adverse events observed with the use of HDAC inhibitors were thrombocytopenia, neutropenia, anemia, fatigue and diarrhea [48,56,74,86,108,109].”